Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2023
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+5.36%
|
-
|
|
Feb 17
2023
|
Doug Samuelson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+50.0%
|
-
|
|
Jan 30
2023
|
Aladar Szalay |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+32.87%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Indirect |
8,176
+50.0%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Direct |
3,186
+50.0%
|
-
|
|
Jan 30
2023
|
John Thomas Director |
BUY
Conversion of derivative security
|
Direct |
470,000
+50.0%
|
-
|
|
Jan 26
2023
|
Qian Zhang Associate VP, Research |
BUY
Open market or private purchase
|
Indirect |
200
+50.0%
|
$1,200
$6.25 P/Share
|